00:49:38 (BST) 00:49:38 (BST)
CSE news on AMBEEPHA
2025-04-28: Un-audited Financial Statements
AMBEEPHA: (Quarter 3) As per un-audited financial statements of the Company, EPS was Tk. 0.85 for January-March 2025 as against Tk. 0.80 for January-March 2024; EPS was Tk. 2.17 for July 2024-March 2025 as against Tk. 2.00 for July 2023-March 2024. NOCFPS was Tk. (5.69) for July 2024-March 2025 as against Tk. (12.21) for July 2023-March 2024. NAV per share was Tk. 13.43 as on March 31, 2025 and Tk. 12.26 as on June 30, 2024.
2025-04-22: Board Meeting
AMBEEPHA: The Company has informed that the Board Meeting will be held on April 27, 2025 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2025.
2025-04-22: Change of Close Price
AMBEEPHA: Please note that the close price of the shares of AMBEEPHA has been reset at current market price prevailing in other exchange. New close price of AMBEEPHA =Tk. 799.50.
2025-02-10: Cash Dividend Disbursement
AMBEEPHA: The Company has informed that it has disbursed the Cash Dividend for the year ended June 30, 2024 to the respective shareholders.
2025-01-23: Un-audited HY A/Cs
AMBEEPHA: (Quarter 2) As per un-audited half yearly accounts of the company, EPS was Tk. 0.62 for October-December 2024 as against Tk. 0.60 for October-December 2023; EPS was Tk. 1.32 for July-December 2024 as against Tk. 1.20 for July-December 2023. NOCFPS was Tk. (19.54) for July-December 2024 as against Tk. (5.61) for July-December 2023. NAV per share was Tk. 12.58 as on December 31, 2024 and Tk. 12.26 as on June 30, 2024.
2025-01-16: Board Meeting
AMBEEPHA: The company has informed that the Board Meeting of the Company will be held on January 22, 2025 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2024.
2024-12-01: Record Date on 02.12.2024
AMBEEPHA: Trading of the shares of the Company will remain suspended on its record date i.e., 02.12.2024. Trading of the shares of the Company will resume on 03.12.2024.
2024-11-27: Spot trade from tomorrow (28.11.2024)
AMBEEPHA: Trading of the shares of the Company will be allowed only in the Spot Market from 28.11.2024 to 01.12.2024 as the record date of the Company is on 02.12.2024.
2024-11-17: Un-audited Financial Statements
AMBEEPHA: (Quarter 1) As per un-audited financial statements of the Company, EPS was Tk. 0.70 for July-September 2024 as against Tk. 0.60 for July-September 2023; NOCFPS was Tk. (6.43) for July-September 2024 as against Tk. (0.49) for July-September 2023. NAV per share was Tk. 12.96 as on September 30, 2024 and Tk. 12.26 as on June 30, 2024.
2024-11-11: CB Free
AMBEEPHA: Please note that there will be no price limit today 11.11.2024 on the trading of the shares of the company following its corporate declaration.
2024-11-11: Recommendation of Dividend
AMBEEPHA: The Board of Directors has recommended 10% Cash Dividend for the year ended June 30, 2024. Date of AGM: 24.12.2024, Time: 11:00 AM, Venue: Online/Digital Platform; 184/1, Tejgaon Industrial Area, Dhaka-1208. Record Date: 02.12.2024. The Company has also reported EPS of Tk. 4.03, NAV per share of Tk. 12.26 and NOCFPS of Tk. (27.47) for the year ended June 30, 2024 as against Tk. 3.79, Tk. 9.73 and Tk. (14.68) respectively for the year ended June 30, 2023.
2024-11-10: Board Meeting
AMBEEPHA: The Company has informed that the Board Meeting of the Company will be held on November 14, 2024 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended September 30, 2024.
2024-11-04: Board Meeting
AMBEEPHA: The Company has informed that a Board Meeting will be held on November 10, 2024 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2024.
2024-10-08: Change of Close Price
AMBEEPHA: Please note that the close price of the shares of AMBEEPHA has been reset at current market price prevailing in other exchange. New close price of AMBEEPHA =Tk. 761.60.
2024-07-07: Credit Rating
AMBEEPHA: ARGUS Credit Rating Services Limited (ACRSL) has announced the rating of the Company as ''A'' in the long term and ''ST-2'' in the short term along with Stable outlook in consideration of audited financials of the company up to June 30, 2023 and unaudited financials up to the period ending March 31, 2024 and other relevant quantitative as well as qualitative information up to the date of rating declaration.
2024-04-29: Un-audited Financial Statements
AMBEEPHA: (Quarter 3) As per un-audited financial statements of the Company, EPS was Tk. 0.80 for January-March 2024 as against Tk. 0.70 for January-March 2023; EPS was Tk. 2.00 for July 2023-March 2024 as against Tk. 1.34 for July 2022-March 2023. NOCFPS was Tk. (12.21) for July 2023-March 2024 as against Tk. 0.38 for July 2022-March 2023. NAV per share was Tk. 10.23 as on March 31, 2024 and Tk. 9.73 as on June 30, 2023.
2024-04-23: Cash Dividend Disbursement
AMBEEPHA: The Company has informed that it has disbursed the Cash Dividend for the year ended June 30, 2023 to the respective shareholders.
2024-04-22: Board Meeting
AMBEEPHA: The Company has informed that the Board Meeting of the Company will be held on April 28, 2024 at 03:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2024.
2024-01-29: Un-audited HY A/Cs
AMBEEPHA: (Quarter 2) As per un-audited half yearly accounts of the company, EPS was Tk. 0.60 for October-December 2023 as against Tk. 0.35 for October-December 2022; EPS was Tk. 1.20 for July-December 2023 as against Tk. 0.60 for July-December 2022. NOCFPS was Tk. (5.61) for July-December 2023 as against Tk. 7.69 for July-December 2022. NAV per share was Tk. 9.43 as on December 31, 2023 and Tk. 9.73 as on June 30, 2023.
2024-01-21: Board Meeting
AMBEEPHA: The Company has informed that the Board Meeting of the Company will be held on January 28, 2024 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2023.
2023-11-22: Record Date tomorrow (23.11.2023)
AMBEEPHA: Trading of the shares of Ambee Pharmaceuticals PLC will remain suspended on its record date i.e., 23.11.2023. Trading of the shares of the Company will resume on 26.11.2023.
2023-11-20: Spot trade from tomorrow (21.11.2023)
AMBEEPHA: Trading of the shares of Ambee Pharmaceuticals PLC will be allowed only in the Spot Market from 21.11.2023 to 22.11.2023 as the record date of the Company is on 23.11.2023.
2023-11-15: Qualified Opinion
AMBEEPHA: The auditor of the company has given the "Qualified Opinion" paragraph in the Auditor's Report of the company for the year ended June 30, 2023. To view the details, please visit: https://www.cse.com.bd/upload_media/Qualified_Opinion_of_Ambee_Pharmaceuticals_PLC_for_the_year_ended_on_30_June_2023.pdf
2023-11-15: Un-audited Financial Statements
AMBEEPHA: (Quarter 1) As per un-audited financial statements of the Company, EPS was Tk. 0.60 for July-September 2023 as against Tk. 0.25 for July-September 2022; NOCFPS was Tk. (0.49) for July-September 2023 as against Tk. 4.34 for July-September 2022. NAV per share was Tk. 10.33 as on September 30, 2023 and Tk. 9.73 as on June 30, 2023.
2023-11-09: Change of AGM Time
AMBEEPHA: Refer to their earlier news disseminated by CSE on 05.11.2023 regarding Recommendation of Dividend and increase of paid up capital, Ambee Pharmaceuticals PLC has further informed that the time of AGM will be 4:00 PM instead of 11:00 AM. The date and venue of the AGM will remain unchanged.
2023-11-08: Board Meeting
AMBEEPHA: Ambee Pharmaceuticals Ltd. has informed that a meeting of the Board of Directors of the Company will be held on November 14, 2023 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended September 30, 2023.
2023-11-05: CB Free
AMBEEPHA: Please note that there will be no price limit today 05.11.2023 on the trading of the shares of the company following its corporate declaration. However, the floor price shall be applicable accordingly.
2023-11-05: Recommendation of Dividend and increase of paid up capital
AMBEEPHA: The Board of Directors has recommended 15% Cash Dividend for the year ended June 30, 2023. Date of AGM: 14.12.2023, Time: 11:00 AM, Venue: Digital Platform. Record date: 23.11.2023. The Company has also reported EPS of Tk. 3.79, NAV per share of Tk. 9.73 and NOCFPS of Tk. (14.68) for the year ended June 30, 2023 as against Tk. 3.36, Tk. 21.96 and Tk. (30.49) respectively for the year ended June 30, 2022. The Board also recommended paid up capital to be increased from TK. 2.40 Crore to TK. 30.00 Crore.
2023-10-26: Board Meeting
AMBEEPHA: Ambee Pharmaceuticals Ltd. has informed that a meeting of the Board of Directors of the Company will be held on November 02, 2023 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2023.
2023-10-05: Query Response
AMBEEPHA: In response to a DSE query dated September 27, 2023, Ambee Pharmaceuticals PLC has informed that there is no undisclosed price sensitive information of the company for recent unusual price hike and increase in volume of shares.
2023-08-01: Name Change of the Company
AMBEEPHA: Chittagong Stock Exchange PLC (CSE) has approved the proposed name change of the Company. Accordingly, the name of the Company will be 'Ambee Pharmaceuticals PLC' instead of 'Ambee Pharmaceuticals Ltd.' with effect from August 02, 2023. Other things (except name) will remain unchanged.
2023-04-17: Un-audited Financial Statements
AMBEEPHA: (Quarter 3) As per un-audited financial statements of Ambee Pharmaceuticals Ltd., EPS was Tk. 0.70 for January-March 2023 as against Tk. 0.40 for January-March 2022; EPS was Tk. 1.34 for July 2022-March 2023 as against Tk. 0.74 for July 2021-March 2022. NOCFPS was Tk. 0.38 for July 2022-March 2023 as against Tk. 2.18 for July 2021-March 2022. NAV per share was Tk. 19.02 as on March 31, 2023 and Tk. 21.96 as on June 30, 2022.
2023-04-16: Board Meeting
AMBEEPHA: Ambee Pharmaceuticals Ltd. has informed that a meeting of the Board of Directors of the Company will be held on April 16, 2023 at 2:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2023.
2023-04-03: Appointment of Company Secretary
AMBEEPHA: Ambee Pharmaceuticals Ltd. has informed that the Board of Directors has approved Mr. Mohammad Amir Hossain as Company Secretary of the company with effect from April 01, 2023.
2023-02-05: Cash Dividend Disbursement
AMBEEPHA: Ambee Pharmaceuticals Ltd. has informed that it has disbursed the cash dividend for the year ended June 30, 2022 to the respective shareholders.
2023-01-26: Un-audited HY A/Cs
AMBEEPHA: (Quarter 2) As per un-audited half yearly accounts of Ambee Pharmaceuticals Ltd., EPS was Tk. 0.35 for October-December, 2022 as against Tk. 0.24 for October-December, 2021; EPS was Tk. 0.60 for July-December, 2022 as against Tk. 0.34 for July-December, 2021. NOCFPS was Tk. 7.69 for July-December, 2022 as against Tk. 4.21 for July-December, 2021. NAV per share was Tk. 21.56 as on December 31, 2022 and Tk. 21.96 as on June 30, 2022. Reasons for Deviation in NOCFPS: NOCFPS increased due to decrease of payments for cost and expenses.
2023-01-19: Board Meeting
AMBEEPHA: Ambee Pharmaceuticals Ltd. has informed that a meeting of the Board of Directors of the Company will be held on January 25, 2023 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2022.
2023-01-11: Change of Close Price
AMBEEPHA: Please note that the close price of the shares of AMBEEPHA has been reset at current market price prevailing in other exchange. New close price of AMBEEPHA=Tk. 479.20.
2023-01-02: BSEC rejected issuance of 20% Stock Dividend
AMBEEPHA: Refer to their earlier news disseminated by CSE on 23.11.2022 regarding Recommendation of Dividend (Additional Information), Ambee Pharmaceuticals Ltd. has further informed that the decision regarding raising of paid-up capital through issuance of 20% stock dividend for the year ended June 30, 2022 has not been approved by Bangladesh Securities and Exchange Commission.
2022-12-11: Record Date tomorrow (12.12.2022)
AMBEEPHA: Trading of the shares of Ambee Pharmaceuticals Ltd. will remain suspended on its record date i.e., 12.12.2022. Trading of the shares of the Company will resume on 13.12.2022.
2022-12-11: Regarding record date for entitlement of Stock Dividend
AMBEEPHA: Refer to their earlier news disseminated by CSE on 22.11.2022 regarding Recommendation of Dividend and Increase of Authorized Capital, Ambee Pharmaceuticals Ltd. has further informed that they made an application to BSEC for issuance of 20% Stock dividend but they have not received approval yet. So they will notify another record date later for entitlement of Stock Dividend if they get approval from BSEC. However, the record date as on 12.12.2022 will be applicable for entitlement of 10% Cash dividend.
2022-12-07: Spot trade from tomorrow (08.12.2022)
AMBEEPHA: Trading of the shares of Ambee Pharmaceuticals Ltd. will be allowed only in the Spot Market from 08.12.2022 to 11.12.2022 as the record date of the Company is on 12.12.2022.
2022-12-06: Cont2-Qualified Opinion
AMBEEPHA(cont2): 3. As disclosed in note # 20.00, the company has shown an amount of Tk. 2,356,352 as Unclaimed Dividend as at 30.06.2022. The amount has arrived at after payment of Tk. 1,500,000 to the Capital Market Stabilization Fund (CMSF) as per directive of Bangladesh Securities and Exchange Commission (BSEC) No. SEC/SRMlC/165-2020/part-1/202 dated 25 August 2021. The designated bank account for dividend has shown a balance of Tk. 153,954 as at 30.06.2022. Hence, there is a shortfall in the dividend bank account. This is a non-compliance of the section 28 (1) of Dhaka Stock Exchange (Listing) Regulations, 2015."(end)
2022-12-06: Cont1-Qualified Opinion
AMBEEPHA(cont1): Incase of failure penalty as per section 236 may be imposed. However, for utilization of the fund the company provided interest as per section 240. 2. As disclosed in note # 17.02, the company has shown Tk. 1,916,358 as Payable to Provident Fund. The amount is carried forward from earlier years. As no Financial Statement of Provident Fund was made available to us, so we are not sure whether there is any forfeited fund returned to company's account from the contributory provident fund as per notification no. 179/FRC/FRM/2020/2, dated July 07, 2020 of the Financial Reporting Council (FRC).(cont2)
2022-12-06: Qualified Opinion
AMBEEPHA: The auditor of the Ambee Pharmaceuticals Ltd. has given the "Qualified Opinion" paragraph in the Auditor's Report for the year ended June 30, 2022. "Basis for Qualified Opinion: 1. As disclosed in note # 19.00, the company has shown Tk. 10,459,676 as liabilities for WPF & WWF which includes prior year's amount of Tk. 9,948,826. Out of the prior year's amount an amount of Tk. 1,144,988 has been paid by the company. As per section 234 (b) of Labour Act, 2006 the company should pay the amount to the WPF & WWF not later than nine months from the end of the respective year.(cont1)
2022-11-28: Un-audited Financial Statements
AMBEEPHA: (Quarter 1) As per un-audited financial statements of Ambee Pharmaceuticals Ltd., EPS was Tk. 0.25 for July-September 2022 as against Tk. 0.10 for July-September 2021; NOCFPS was Tk. 4.34 for July-September 2022 as against Tk. 8.37 for July-September 2021. NAV per share was Tk. 22.20 as on September 30, 2022 and Tk. 21.96 as on June 30, 2022.
2022-11-23: Update of Information
AMBEEPHA: Ambee Pharmaceuticals Ltd. has requested the Shareholders who changed/amended their e-mail addresses or opened new e-mail addresses after the Record Date to e-mail the details to cs@ambeepharma.com along with full name, Folio/BO ID to receive the digital platform meeting invitation. The Company has also requested the Shareholders to notify 12-digit Taxpayer's Identification Number (E-TIN) through their respective Depository Participants.
2022-11-23: Cont-Recommendation of Dividend (Additional Information)
AMBEEPHA:(cont) iii) They have not declared such stock dividend or bonus shares from capital reserve or revaluation reserve or any unrealized gain or out of profit earned prior to incorporation of the company or through reducing paid up capital or through doing anything so that the post-dividend retained earnings become negative or a debit balance.(end)
2022-11-23: Recommendation of Dividend (Additional Information)
AMBEEPHA: Ambee Pharmaceuticals Ltd. has further informed that the stock dividend declared by them is subject to the approval of Bangladesh Securities and Exchange Commission as per BSEC Notification No. BSEC/CMRRCD/2009-193/46/Admin/138 dated October 03, 2022. Record date: 12.12.2022. The company has also informed that i) The reason for the declaration of Stock Dividend is to raise minimum paid-up capital of Tk. 30.00 crore as per regulatory requirement. ii) They have declared the Stock Dividend from the profit of Financial Year 2021- 2022. (cont)
2022-11-22: (Correction)Recommendation of Dividend
AMBEEPHA (Correction): The Conditions will be 2 and 3(c) of BSEC Notification instead of Conditions 2 and 3(a) of BSEC Notification. Other information will remain unchanged.
2022-11-22: CB Free
AMBEEPHA: Please note that there will be no price limit today 22.11.2022 on the trading of the shares of the company following its corporate declaration, however, as per the BSEC Order No. BSEC/CMRRCD/2001-07/39 dated July 28, 2022, the floor price shall be applicable accordingly.
2022-11-22: Cont-Recommendation of Dividend
AMBEEPHA(cont):for the same period of the previous year. The company has further informed that the following agenda as special business, among others, will be placed for approval in the AGM: i) To change the name of the Company from Ambee Pharmaceuticals Limited to Ambee Pharmaceuticals PLC as to amend Clause 1 of Memorandum of Association of the Company. ii) To increase the Authorized Capital of the Company from Tk. 2.50 crore to Tk. 30.00 crore and to amend the Clause 5 and Article 4 and Article 53 of the Memorandum and Articles of Association of the Company.(end)
2022-11-22: Recommendation of Dividend
AMBEEPHA: The Board of Directors has recommended 10% Cash and 20% Stock dividend for the year ended June 30, 2022. DSE has sent a query letter to the company as they have not complied Conditions 2 and 3(a) of BSEC Notification No.- BSEC/CMRRCD/2009-193/46/Admin/138 dated October 03, 2022 regarding declaration of stock dividend. Date of AGM: 31.12.2022, Time: 11:00 AM, Venue: Digital Platform. Record date: will be notified later on. The Company has also reported EPS of Tk. 3.36, NAV per share of Tk. 21.96 and NOCFPS of Tk. (30.49) for the year ended June 30, 2022 as against Tk. (5.42), Tk. 18.68 and Tk. (2.27) respectively(cont)
2022-11-22: Board Meeting
AMBEEPHA: Ambee Pharmaceuticals Ltd. has informed that a meeting of the Board of Directors of the Company will be held on November 27, 2022 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended September 30, 2022.
2022-11-17: Board Meeting
AMBEEPHA: Ambee Pharmaceuticals Ltd. has informed that a meeting of the Board of Directors will be held on November 21, 2022 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2022.
2022-08-08: Vice Chairperson and CEO
AMBEEPHA: Ambee Pharmaceuticals Ltd. has informed that the Board of Directors of the Company has appointed Mrs. Naureen Aziz Mohammad Bhai as Vice Chairperson and Chief Executive Officer (CEO) with effect from 16 June 2022.
2022-07-24: Change of Close Price
AMBEEPHA: Please note that the close price of the shares of AMBEEPHA has been reset at current market price prevailing in other exchange. New close price of AMBEEPHA =Tk. 488.40.
2022-04-28: Un-audited Financial Statements
AMBEEPHA: (Quarter 3) As per un-audited financial statements of Ambee Pharmaceuticals Ltd., EPS was Tk. 0.40 for January-March 2022 as against Tk. 0.30 for January-March 2021; EPS was Tk. 0.74 for July 2021-March 2022 as against Tk. 0.65 for July 2020-March 2021. NOCFPS was Tk. 2.18 for July 2021-March 2022 as against Tk. 3.89 for July 2020-March 2021. NAV per share was Tk. 19.42 as on March 31, 2022 and Tk. 18.68 as on June 30, 2021.
2022-04-21: Board Meeting
AMBEEPHA: Ambee Pharmaceuticals Ltd. has informed that a meeting of the Board of Directors will be held on April 27, 2022 at 2:30 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2022.
2022-03-02: Credit Rating
AMBEEPHA: The Bangladesh Rating Agency Limited (BDRAL) has assigned the rating to Ambee Pharmaceuticals Ltd. as ''A-'' in the long term and ''ST-3'' in the short term along with a developing outlook based on audited financials up to June 30, 2021, unaudited financials up to December 31, 2021 and other relevant quantitative as well as qualitative information up to the date of rating declaration.
2022-01-30: Un-audited HY A/Cs
AMBEEPHA: (Quarter 2) As per un-audited half yearly accounts of Ambee Pharmaceuticals Ltd., EPS was Tk. 0.24 for October-December, 2021 as against Tk. 0.20 for October-December, 2020; EPS was Tk. 0.34 for July-December, 2021 as against Tk. 0.35 for July-December, 2020. NOCFPS was Tk. 4.21 for July-December, 2021 as against Tk. 0.54 for July-December, 2020. NAV per share was Tk. 18.92 as on December 31, 2021 and Tk. 18.68 as on June 30, 2021.
2022-01-24: Board Meeting
AMBEEPHA: The Company has informed that a meeting of the Board of Directors will be held on January 27, 2022 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2021.
2021-12-02: Record Date on 05.12.2021
AMBEEPHA: Trading of the shares of Ambee Pharmaceuticals Ltd. will remain suspended on its record date i.e., 05.12.2021. Trading of the shares of the Company will resume on 06.12.2021.
2021-11-30: Spot trade from tomorrow (01.12.2021)
AMBEEPHA: Trading of the shares of Ambee Pharmaceuticals Ltd. will be allowed only in the Spot Market from 01.12.2021 to 02.12.2021 as the record date of the Company is on 05.12.2021.
2021-11-23: Un-audited Financial Statements
AMBEEPHA: (Quarter 1) As per un-audited financial statements of Ambee Pharmaceuticals Ltd., EPS was Tk. 0.10 for July-September 2021 as against Tk. 0.15 for July-September 2020; NOCFPS was Tk. 8.37 for July-September 2021 as against Tk. 0.68 for July-September 2020. NAV per share was Tk. 18.79 as on September 30, 2021 and Tk. 18.68 as on June 30, 2021.
2021-11-21: Cont2-Auditor's Opinion
AMBEEPHA(cont2):and in compliance with clause 3 (vii) of the Bangladesh Securities and Exchange Commission (BSEC) Directive No. BSEC/CMRRCD/2021-386/03, dated 14 January 2021. Emphasis of Matter: In forming our opinion on the Financial Statements, which is not modified, we considered the following matter and the fact that as per note # 10.01, the company reported an amount of Tk. 12,796,385 as cash in hand. Physical counting of cash in hand at Head Office for Tk. 13,548 and Factory for Tk. 4,357 only was done by the management at the year-end."(end)
2021-11-21: Cont1-Auditor's Opinion
AMBEEPHA(cont1):As no financial statement of Provident Fund was made available to us, so we are not sure whether there is any forfeited fund returned to company's account from the contributory provident fund as per notification no. 179/FRC/FRM/2020/2, dated July 07, 2020 of the Financial Reporting Council (FRC). 3. As disclosed in note # 21.00, the company has shown Tk. 3,856,352 as Unclaimed Dividend. As the company has no designated bank account for dividend, so we are not sure whether the dividend was paid to the shareholders within the stipulated time as per section 28(1) of Dhaka Stock Exchange (Listing) Regulations, 2015 (cont2)
2021-11-21: Auditor's Opinion
AMBEEPHA: The auditor of Ambee Pharmaceuticals Ltd. has given the "Qualified Opinion" and "Emphasis of Matter" in the audit report for the year ended on 30 June, 2021. "Basis for Qualified Opinion: 1. As disclosed in note # 20.00, the company has shown Tk. 9,948,826 as liabilities for WPF & WWF which includes prior year's amount of Tk. 9,127,363 that has not been paid by the company to the Fund. As per section 234 (b) of Labour Act, 2006 the company should pay the amount to the WPF & WWF not later than nine months from the end of the respective year. 2. As disclosed in note # 18.02, the company has shown Tk. 1,916,358 as Payable to Provident Fund. The amount is carried forward from earlier years.(cont1)
2021-11-18: Board Meeting
AMBEEPHA: Ambee Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on November 22, 2021 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended on September 30, 2021.
2021-11-14: Recommendation of No Dividend (Additional Information)
AMBEEPHA: Ambee Pharmaceuticals Ltd. has further informed that Net Operating Cash Flow per share will be (2.27) instead of (2.77) for the year ended on June 30, 2021.
2021-11-14: CB Free
AMBEEPHA: Please note that there will be no price limit today 14.11.2021 on the trading of the shares of the company following its corporate declaration.
2021-11-14: Recommendation of No Dividend
AMBEEPHA: The Board of Directors has recommended no dividend for the year ended on June 30, 2021. Date of AGM: 28.12.2021, Time: 11:00 AM, Venue: digital platform. Record date: 05.12.2021. The Company has also reported EPS of Tk. (5.42), NAV per share of Tk. 18.68 and NOCFPS of Tk. (2.77) for the year ended on June 30, 2021 as against Tk. 1.52, Tk. 24.10 and Tk. (4.99) respectively for the same period of the previous year.
2021-11-07: Board Meeting
AMBEEPHA: Ambee Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on November 11, 2021 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2021.
2021-09-20: Cash Dividend Disbursement
AMBEEPHA: Ambee Pharmaceuticals Ltd. has informed that it has disbursed the cash dividend for the year ended on June 30, 2020 to the respective shareholders.
2021-09-13: Query Response
AMBEEPHA: In response to a DSE query dated September 12, 2021, Ambee Pharmaceuticals Ltd. has informed that there is no undisclosed price sensitive information of the Company for recent unusual price hike and increase in volume of shares.
2021-08-18: Un-audited Financial Statements
AMBEEPHA: (Quarter 3) As per un-audited financial statements of Ambee Pharmaceuticals Ltd., EPS was Tk. 0.30 for January-March 2021 as against Tk. 0.75 for January-March 2020; EPS was Tk. 0.65 for July 2020-March 2021 as against Tk. 2.38 for July 2019-March 2020. NOCFPS was Tk. 3.89 for July 2020-March 2021 as against Tk. 0.09 for July 2019-March 2020. NAV per share was Tk. 23.25 as on March 31, 2021 and Tk. 24.10 as on June 30, 2020.
2021-08-18: Un-audited HY A/Cs
AMBEEPHA: (Quarter 2) As per un-audited half yearly accounts of Ambee Pharmaceuticals Ltd., EPS was Tk. 0.20 for October-December, 2020 as against Tk. 0.88 for October-December, 2019; EPS was Tk. 0.35 for July-December, 2020 as against Tk. 1.63 for July-December, 2019. NOCFPS was Tk. 0.54 for July-December, 2020 as against Tk. 0.07 for July-December, 2019. NAV per share was Tk. 22.95 as on December 31, 2020 and Tk. 24.10 as on June 30, 2020.
2021-08-18: Un-audited Financial Statements
AMBEEPHA: (Quarter 1) As per un-audited financial statements of Ambee Pharmaceuticals Ltd., EPS was Tk. 0.15 for July-September 2020 as against Tk. 0.75 for July-September 2019; NOCFPS was Tk. 0.68 for July-September 2020 as against Tk. 0.44 for July-September 2019. NAV per share was Tk. 24.25 as on September 30, 2020 and Tk. 24.10 as on June 30, 2020.
2021-08-11: Board Meeting
AMBEEPHA: Ambee Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on August 17, 2021 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended on September 30, 2020, Second Quarter (Q2) period ended on December 31, 2020 & Third Quarter (Q3) period ended on March 31, 2021.
2021-06-27: Record Date tomorrow (28.06.2021)
AMBEEPHA: Trading of the shares of Ambee Pharmaceuticals Ltd. will remain suspended on its record date i.e., 28.06.2021. Trading of the shares of the Company will resume on 29.06.2021.
2021-06-23: Spot trade from tomorrow (24.06.2021)
AMBEEPHA: Trading of the shares of Ambee Pharmaceuticals Ltd. will be allowed only in the Spot Market from 24.06.2021 to 27.06.2021 as the record date of the Company is on 28.06.2021.
2021-06-15: Cont-Auditor's Opinion
AMBEEPHA(cont):the company filed an application to the Hon'ble High Court for condonation of default for not holding the AGM in time. In hearing the petition, the Hon'ble High Court in its' verdict has accepted the condonation petition and directed the company to hold the AGM within eight weeks on receipt of the copy of verdict. However, the company received the verdict on 01-06-2021.''(end)
2021-06-15: Auditor's Opinion
AMBEEPHA: The auditor of Ambee Pharmaceuticals Ltd. has given the following ''Qualified Opinion'' and ''Emphasis of Matter'' in the audit report of the Company for the year ended on 30 June 2020: ''Basis for Qualified Opinion: The Company has not disclosed BDT 18,000,000 as VAT payable in their VAT return. Emphasis of Matter: Due to some unavoidable circumstances, AGM of the company could not be held in time and accordingly,(cont)
2021-06-08: CB Free
AMBEEPHA: Please note that there will be no price limit today 08.06.2021 on the trading of the shares of the Company following its corporate declaration, however, as per the BSEC Order No. BSEC/CMRRCD/2001-07/04 dated March 19, 2020, the floor price shall be applicable accordingly.
2021-06-08: Recommendation of Dividend
AMBEEPHA: The Board of Directors has recommended 15% cash dividend for the year ended on June 30, 2020. Date of AGM: 13.07.2021, Time: 11:00 AM, Venue: digital platform. Record date: 28.06.2021. The Company has also reported EPS of Tk. 1.52, NAV per share of Tk. 24.10 and NOCFPS of Tk. (4.99) for the year ended on June 30, 2020 as against Tk. 1.40, Tk. 24.09 and Tk. 16.42 respectively for the same period of the previous year.
2021-05-31: Board Meeting
AMBEEPHA: Ambee Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on June 7, 2021 at 3:15 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2020.
2020-12-27: Credit Rating
AMBEEPHA: ARGUS Credit Rating Services Limited (ACRSL) has announced the rating of Ambee Pharmaceuticals Ltd. as ''A'' for long term and ''ST-2'' for short term with stable outlook in consideration of audited financials of the Company up to June 30, 2019, unaudited financials up to the period ending March 31, 2020 and other relevant quantitative as well as qualitative information up to the date of rating declaration.
2020-09-24: Change of Close Price
AMBEEPHA: Please note that the close price of the shares of AMBEEPHA has been reset at current market price prevailing in other exchange. New close price of AMBEEPHA =Tk. 488.60.
2020-06-14: Un-audited Financial Statements
AMBEEPHA: (Quarter 3) As per un-audited financial statements of Ambee Pharmaceuticals Ltd., EPS was Tk. 0.75 for January-March 2020 as against Tk. 0.85 for January-March 2019; EPS was Tk. 2.38 for July 2019-March 2020 as against Tk. 2.54 for July 2018-March 2019. NOCFPS was Tk. 0.09 for July 2019-March 2020 as against Tk. 3.83 for July 2018-March 2019. NAV per share was Tk. 23.47 as on March 31, 2020 and Tk. 24.09 as on June 30, 2019.
2020-06-07: Board Meeting
AMBEEPHA: Ambee Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on June 11, 2020 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended on March 31, 2020.
2020-02-06: Cash Dividend Disbursement
AMBEEPHA: Ambee Pharmaceuticals Ltd. has informed that the Cash dividend of the Company for the year ended on 30 June 2019 has been disbursed.
2020-01-30: Un-audited HY A/Cs
AMBEEPHA: (Quarter 2) As per un-audited half yearly accounts of Ambee Pharmaceuticals Ltd., EPS was Tk. 0.88 for October-December, 2019 as against Tk. 0.85 for October-December, 2018; EPS was Tk. 1.63 for July-December, 2019 as against Tk. 1.69 for July-December, 2018. NOCFPS was Tk. 0.07 for July-December, 2019 as against Tk. 5.66 for July-December, 2018. NAV per share was Tk. 22.72 as on December 31, 2019 and Tk. 24.09 as on June 30, 2019.
2020-01-26: Board Meeting
AMBEEPHA: Ambee Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on January 29, 2020 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2019.
2019-12-15: Record Date on 17.12.2019
AMBEEPHA: Trading of the shares of Ambee Pharmaceuticals Ltd. will remain suspended on its record date i.e., 17.12.2019. Trading of the shares of the Company will resume on 18.12.2019.
2019-12-11: Spot trade from tomorrow (12.12.2019)
AMBEEPHA: Trading of the shares of Ambee Pharmaceuticals Ltd. will be allowed only in the Spot Market from 12.12.2019 to 15.12.2019 as the record date of the Company is on 17.12.2019.
2019-12-01: Un-audited Financial Statements
AMBEEPHA: (Quarter 1) As per un-audited financial statements of Ambee Pharmaceuticals Ltd., EPS was Tk. 0.75 for July-September 2019 as against Tk. 0.84 for July-September 2018; NOCFPS was Tk. 0.44 for July-September 2019 as against Tk. 1.22 for July-September 2018. NAV per share was Tk. 24.84 as on September 30, 2019 and Tk. 24.09 as on June 30, 2019.
2019-11-27: Recommendation of Dividend (Additional Information)
AMBEEPHA: The Company has informed that EPS decreased by Tk. 2.04 due to profit after tax decreased by Tk. 4,896,965 this year than last year. During the year earlier year income taxes of Tk. 5,586,300 and interest on WPPF Fund of Tk. 940,672 which relates to previous year have been charged as expenses for the year resulting decrease of EPS. NOCFPS increased in this year by Tk. 8.66 due to increase of collection against sales by 3.05% than last year and decrease of operating expenses against sales in this year by 1.07 % than last year.
2019-11-27: CB Free
AMBEEPHA: Please note that there will be no price limit today 27 November 2019 on the trading of shares of the Company following its corporate disclosure.
2019-11-27: Recommendation of Dividend
AMBEEPHA: The Board of Directors has recommended 30% cash dividend for the year ended on June 30, 2019. Date of AGM: 31.12.2019, Time: 10:00 AM, Venue: Factory Premises, 184/1 Tejgaon Industrial Area, Dhaka-1208. Record date: 17.12.2019. The Company has also reported EPS of Tk. 1.40, NAV per share of Tk. 24.09 and NOCFPS of Tk. 16.42 for the year ended on June 30, 2019 as against Tk. 3.44, Tk. 25.68 and Tk. 7.76 respectively for the same period of the previous year.
2019-11-25: Board Meeting
AMBEEPHA: Ambee Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on November 28, 2019 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended on September 30, 2019.
2019-11-20: Credit Rating
AMBEEPHA: ARGUS Credit Rating Services Limited (ACRSL) has announced the rating of Ambee Pharmaceuticals Ltd. as ''A'' for long term and ''ST-2'' for short term in consideration of audited financials of the Company up to June 30, 2018, unaudited financials up to the period ending March 31, 2019 and other relevant quantitative as well as qualitative information up to the date of rating declaration.
2019-11-18: Board Meeting
AMBEEPHA: Ambee Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on November 26, 2019 at 3:15 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2019.
2019-01-30: Un-audited HY A/Cs
AMBEEPHA: (Quarter 2) As per un-audited half yearly accounts of Ambee Pharmaceuticals Ltd., EPS was Tk. 0.85 for October-December, 2018 as against Tk. 0.82 for October-December, 2017; EPS was Tk. 1.69 for July-December, 2018 as against Tk. 1.57 for July-December, 2017. NOCFPS was Tk. 5.66 for July-December, 2018 as against Tk. 3.46 for July-December, 2017. NAV per share was Tk. 24.38 as on December 31, 2018 and Tk. 25.68 as on June 30, 2018.
2019-01-28: Cash Dividend Disbursement
AMBEEPHA: Ambee Pharmaceuticals Ltd. has informed that the Cash dividend of the Company for the year ended on 30 June 2018 has been disbursed.
2019-01-24: Board Meeting
AMBEEPHA: Ambee Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on January 29, 2019 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2018.
2018-12-05: Cont2-Auditor's Opinion
AMBEEPHA(cont2): During the year, previous year's payment for costs, expenses & others in statement of cash flows have been rearranged by increasing Taka 6,573,133.00 and adjusting cash flows from financing activities resulting decrease in cash generated from operating activities. As a result, net operating cash flow per share of previous year of Taka 10.33 has been reduced to Taka 7.59. This was due to some wrong treatments of debit/credit balances of loan accounts.''(end)
2018-12-05: Cont1-Auditor's Opinion
AMBEEPHA(cont1): which was due to wrong treatment of some accounts. Note: 28.00 Net Operating Cash Flow per share for the year 2017-18: Cash flows from net operating activities as per Statement of Cash flows Tk. 18,626,052.00, Weighted average number of Ordinary shares outstanding during the year 2,400,000 and Net Operating Cash Flow per share Tk. 7.76. Net Operating Cash Flow per share for the year 2016-17: Cash flows from net operating activities as per Statement of Cash flows Tk. 18,225,025.00, Weighted average number of Ordinary shares outstanding during the year 2,400,000 and Net Operating Cash Flow per share Tk. 7.59.(cont2)
2018-12-05: Auditor's Opinion
AMBEEPHA: The auditor of Ambee Pharmaceuticals Ltd.has given the following Emphasis of Matter in the audit report of the Company for the year ended on 30 June 2018: ''Emphasis of Matter: i) The company has not properly complied with section 234 (l)(b) of Bangladesh Labor Law 2006 (as amended in 2013) of WPPF rules regarding distribution of the fund and interest payable thereon. ii) We refer to note-28 regarding Net Operating Cash Flow per share in which previous years' figure of Taka 10.33 has been reduced to Taka 7.59 (reduced 2.74 Taka per share)(cont1)
2018-12-03: Record Date tomorrow (04.12.2018)
AMBEEPHA: Trading of the shares of Ambee Pharmaceuticals Ltd. will remain suspended on its record date i.e., 04.12.2018. Trading of the shares of the Company will resume on 05.12.2018.
2018-11-29: Spot trade from 02.12.2018
AMBEEPHA: Trading of the shares of Ambee Pharmaceuticals Ltd. will be allowed only in the Spot Market from 02.12.2018 to 03.12.2018 as the record date of the Company is on 04.12.2018.
2018-11-27: Query Response
AMBEEPHA: In response to a DSE query dated November 26, 2018, Ambee Pharmaceuticals Ltd. has informed that there is no undisclosed price sensitive information of the Company for recent unusual price hike of shares.
2018-11-15: Un-audited Financial Statements
AMBEEPHA: (Quarter 1) As per un-audited financial statements of Ambee Pharmaceuticals Ltd., EPS was Tk. 0.85 for July-September, 2018 as against Tk. 0.75 for July-September, 2017; NOCFPS was Tk. 1.22 for July-September, 2018 as against Tk. 3.45 for July-September, 2017. NAV per share was Tk. 26.53 as on September 30, 2018 and Tk. 25.68 as on June 30, 2018.
2018-11-13: CB Free
AMBEEPHA: Please note that there will be no price limit today 13 November 2018 on the trading of shares of the Company following its corporate disclosure.
2018-11-13: Recommendation of Dividend
AMBEEPHA: The Board of Directors has recommended 30% Cash Dividend for the year ended on June 30, 2018. Date of AGM: 27.12.2018, Time: 10:00 AM, Venue: 184/1 Tejgaon Industrial Area, Dhaka-1208. Record date: 04.12.2018. The Company has also reported EPS of Tk. 3.44, NAV per share of Tk. 25.68 and NOCFPS of Tk. 7.76 for the year ended on June 30, 2018 as against Tk. 3.02, Tk. 25.24 and Tk. 7.59 respectively for the same period of the previous year.
2018-11-11: Board Meeting
AMBEEPHA: Ambee Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on November 14, 2018 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended on September 30, 2018.
2018-11-05: Board Meeting
AMBEEPHA: Ambee Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on November 12, 2018 at 3:15 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2018.
CSE News
©2024 Chittagong Stock Exchange PLC. All rights reserved.